BACKGROUND
==========

Chronic idiopathic (spontaneous) urticaria (CIU) is a difficult-to-treat illness of uncertain etiology.^[@B1]--[@B3]^ CIU is characterized clinically by the frequent occurrence of pruritic and erythematous wheals with surrounding erythema and, histologically, by a dense perivascular infiltrate composed of basophils, eosinophils, neutrophils, and CD4 and CD8 T-lymphocytes.^[@B4]--[@B7]^ Increased expression of Th1 and Th2 cytokines, TNFα, IL-3, CCL2, and CXCL8 has been reported (for brief descriptions of all genes and gene products mentioned, see [www.genenames.org](http://www.genenames.org)).^[@B8]--[@B10]^ Th17 cells are reported to be decreased.^[@B11]^ Polymorphisms of the high affinity receptor for Immunoglobulin E (IgE), FcεRI, and histamine N-methyltransferase have been described in patients with aspirin intolerant urticaria and have been proposed to be important in CIU.^[@B12]--[@B14]^

METHODS
=======

Subjects
--------

We enrolled eight patients with CIU, two men and six women (mean ± SD, 40 ± 14 years old), based on clinical history and typical urticarial lesions, and six healthy controls, one man and five women (48 ± 12 years old) (*p* = n.s.). This study was approved by the University of Colorado Institutional Review Board. All the subjects signed informed consent forms. Standard doses of antihistamines had failed for each patient; patients had not received steroids or immunomodulatory drugs for 1 month and had stopped all medications except for "as needed" diphenhydramine for 5 days before the biopsy. As shown in [Table 1](#T1){ref-type="table"}, the subjects with CIU were 40 ± 14 years old (compared with 48 ± 12 years old for the controls), the disease had been present for 12.8 ± 12.4 months (range, 4--35 months), had urticaria symptom scores of 14.2 ± 6.5 (range, 11--24), and had lesion scores of 18 to \>100 at the time of the biopsy (each, as described by Breneman *et al.*^[@B15]^). Five of eight subjects had evidence of autoimmunity based on an autologous serum skin test performed as described by Grattan.^[@B16]^ The night before the biopsy, the lesions were circled in black, and, in the morning, new lesions were marked with red. Although the exact age of the lesions was not known, the lesions were likely between 4 and 12 hours old.

###### 

Demographics
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ASST = autologous serum skin test; na = not applicable; ND = not done.

\*mm greater than the saline solution control.

Biopsies
--------

Four millimeter punch biopsy specimens of new lesions were obtained within 4--6 hours after awakening, and, immediately, half of each sample was immersed in optimum cutting temperature compound (OCT) and flash frozen. The other half was immersed in RNAlater (Life Technologies, Grand Island, NY) and stored at −70°C for 6 years.

Gene Expression Analysis
------------------------

RNA of sufficient quantity and quality was recovered from urticarial lesions of seven subjects, nonlesional skin of eight subjects, and normal skin of five controls. RNA was isolated, and gene expression data were determined by using an Affymetrix Human Gene 1.0 ST Array.^[@B17]^ The chip interrogated 28,869 well-annotated genes with 764,885 distinct probes, including 19,734 gene-level probe sets with full length, which provided comprehensive coverage of 99% of the National Center for Biotechnical Information Reference Sequence collection. Data from two patients with urticaria were eliminated from the array study due to quality control concerns (one had poor-quality RNA, and one was a clear outlier, which showed no significant upregulation of message). We analyzed the nonlesional samples only from those subjects with CIU for whom we had an evaluable lesional sample. For the final analysis, we studied six samples of lesional skin, six samples of nonlesional skin, and five samples of normal skin. All RNA was used for the gene chip analysis, so there was insufficient RNA to verify gene expression by specific polymerase chain reaction analysis.

Microarray data were processed by using a robust multiarray average normalization corrected for GC content as implemented by Partek Genomics Suite v6.6 software.^[@B18]^ All normalized data, along with all of the raw Affymetrix Cel files used to generate the data set, has been deposited in the Gene Expression Omnibus.^[@B19]^

Statistics
----------

The Partek Genomics Suite was also used for all statistical analysis of gene expression data (analysis of variance test for significance with a false discovery rate \<0.001 to control for multiple testing) and used to visualize the data by using principle components analysis, an unsupervised analysis of data clustering. Data are expressed as mean (standard deviation) for age, duration of illness, and symptom scores, and are mean ± standard error (SE) for cell counts. A two-tailed Mann-Whitney test was used to compare cell numbers between affected and unaffected skin (GraphPad Prism 5.0c, Macintosh; GraphPad Software Inc., La Jolla, CA). Ingenuity pathway analysis was used to identify overrepresented biologic functions and pathways that contained genes different between lesions and control skin, and based on the direction of expression of the affected genes used to predict their activity.^[@B20]^

RESULTS
=======

Lesions Had Typical Histology
-----------------------------

As expected, lesional skin had more inflammatory cells per high-powered field (mean ± SE, 96 ± 6) than did samples from nonlesional skin of the subjects with CIU (17 ± 2; *p* \< 0.01). These were predominantly mononuclear cells, although both eosinophils and neutrophils were present in most biopsy specimens and were more than that seen in nonlesional skin (*p* \< 0.05) ([Table 2](#T2){ref-type="table"}).
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Histology
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hpf = high powered field; MNC = mononuclear cell; EOS = eosinophil; PMN = neutrophil; cap = capillary; na = not applicable; SE = standard error.

All compared with unaffected skin.

\*p ≤ 0.01.

\#p = 0.03.

Gene Expression Was Highly Consistent
-------------------------------------

Principle components analysis of gene expression data revealed distinct consistency among samples. In [Fig. 1](#F1){ref-type="fig"}, the axes are arbitrary values that summarize the variability in these data points in each of three independent analyses and account for 18% (*x*-axis), 13% (*y*-axis), and 9% (z-axis) of the variability among the samples. Samples from lesional skin ([Fig. 1](#F1){ref-type="fig"}, red spheres) grouped together and clustered on the graph in an area that is distinct compared with samples from the nonlesional skin of subjects with CIU ([Fig. 1](#F1){ref-type="fig"}, blue spheres with lines that connect to matched samples from lesional skin) and from the skin of normal controls ([Fig. 1](#F1){ref-type="fig"}, blue spheres without lines). Although the distribution of the control data indicated that the gene expression profiles from nonlesional skin may be somewhat different from that of skin from normal controls due to the limited sample size, the data from normal skin and from nonlesional skin of patients with CIU were not statistically different and were grouped together for the subsequent analysis.

![Principle component analysis of gene expression data. Urticarial lesions (red) and control skin biopsy specimens (blue) are represented in three-dimensional space based on the global gene expression patterns of each sample. Lesional and control biopsy specimens obtained from the same individual are connected by a line. The biopsy specimens from healthy controls are not associated with lines.](arh0021501240001){#F1}

Multiple Genes Were Upregulated
-------------------------------

Overall, compared with biopsy specimens of normal controls and nonlesional skin combined, lesions of CIU showed significant upregulation of 506 genes and reduced expression of 51 genes (data not shown; see (<http://www.ncbi.nlm.nih.gov/geo/>). The 12 genes most upregulated (by *p* value), the 12 genes most differentially downregulated (by *p* value), and the 12 genes with the largest fold change are listed in [Table 3](#T3){ref-type="table"} (sections A--C, respectively). The genes most differentially upregulated (by *p* value) ([Table 3](#T3){ref-type="table"}, section A) and those with the largest fold change ([Table 3](#T3){ref-type="table"}, section C) are predominantly involved in cell adhesion (*e.g.*, SELE), cell activation (*e.g.*, CD69), and chemotaxis (*e.g.*, CCL2). Of particular note, upregulation of message for CCL2 is consistent with the report by Santos *et al.*^[@B10]^ Those genes that were significantly downregulated ([Table 3](#T3){ref-type="table"}, section B) were not dramatically downregulated and did not share functions that were easy to discern.
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In rank order, the 12 most differentially expressed genes (A), most differentially downregulated genes (B), and genes with the largest fold change (C)
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For specific names of genes and their products, please see [www.genenames.org](http://www.genenames.org).

Two pathways thought to be important in the pathophysiology of chronic urticaria are those associated with mast cells and with the complement system.^[@B1]^ Multiple genes reported to be upregulated by mast cells after activation through the high affinity receptor for IgE were detected, including CSF1 (1.6-fold), IL1R1 (2.5-fold), CCL4 (1.4-fold), CD69 (3.4-fold), TNFAIP6 (28-fold), NFKB1 (2-fold), MYC (2.9-fold), and MAP3K14 (1.3-fold) ([Table 3](#T3){ref-type="table"}, section A and data not shown).^[@B21],[@B22]^ However, most mast cell--related genes that are upregulated after activation tend to revert to baseline levels within 12 hours so that upregulation of other mast cell--related genes may have been missed.^[@B21]^ The only genes associated with the complement system^[@B23]^ that were found to be upregulated were C1QBP (2.01-fold) and ITGAX (1.96-fold) (data not shown).

Canonical and Cellular Function Pathways
----------------------------------------

We next determined which canonical pathways contained genes that are overrepresented ([Table 4](#T4){ref-type="table"}) and which cellular functions include these pathways ([Table 5](#T5){ref-type="table"}). Twelve independent pathways with *p* ≤ 0.001 were identified (including intracellular kinase pathways (RAN and JAK/interferon signaling pathways), cytokine signaling pathways (IL-9, IL10, and IFN), a strong inflammatory response (interferon, IL-9, IL-10, iNOS, and glucocorticoid pathways), and increased cell proliferation (RAN signaling, cell-cycle control, and tRNA charging) ([Table 4](#T4){ref-type="table"}). The two cellular functions that are most dramatically upregulated are those associated with infection (activation z-score = 6.023; *p* = 1.64 × 10^−6^) and more specifically viral infections (activation z-score = 5.1; *p* = 4.97 × 10^−10^) ([Table 5](#T5){ref-type="table"}). Not unexpectedly, genes associated with the cellular functions of growth and proliferation are also highly upregulated (activation z-score = 4.9; *p* = 3.8 × 10^−12^) ([Table 5](#T5){ref-type="table"}).
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In rank order, 12 most activated canonical pathways (by *p* value)
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\*The probability (p value) of obtaining genes associated with the given pathways by random chance.

\#Percentage of genes in the named pathway that were found to be differentially expressed in this study.

†For specific names of genes and their products, please see [www.genenames.org](http://www.genenames.org).
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In rank order, 12 most upregulated cellular functions (by z-score)
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\*For specific names of genes and their products, please see [www.genenames.org](http://www.genenames.org).

DISCUSSION
==========

We undertook this study based on the hypothesis that a study of gene expression in active lesions from patients with CIU would uncover unexpected associations and stimulate new thinking about this challenging condition. Limitations of this study include the small number of subjects, lack of information regarding cell specificity associated with altered gene expression, the single time point sampled, and the lack of verification of gene expression by real-time polymerase chain reaction assays (all of the RNA was used for the gene chip analysis). In that CIU may represent a heterogeneous group of disorders, it is unclear if this small sample of patients with CIU is truly representative of the pathophysiology of this disorder. For example, 62% or our patients with chronic urticaria had evidence of autoimmunity compared with the usual finding of ∼40%. These patients were not routinely checked for thyroid autoimmunity or for antinuclear antibodies.^[@B24]^ Finally, in that only one time point was analyzed, we are unable to make inferences if the observed changes in gene expression may play specific roles in the development or perpetuation of chronic urticaria.

The strengths of this study are the methodology to obtain lesions with highly consistent patterns of gene activation ([Fig. 1](#F1){ref-type="fig"}) and the novel nature of the findings. As expected, samples of lesional skin from patients with chronic urticaria demonstrated high levels of upregulation of multiple genes related to the influx of inflammatory cells into the lesions, and these genes include those seen after activation of mast cells. Upregulation of genes associated with glucocorticoid signaling (including NFKB) was unexpected in that these patients had not received glucocorticoids for at least 1 month before biopsy. Furthermore, the pattern of gene expression seen in this pilot study is different from that reported for other skin diseases (*e.g.*, atopic dermatitis and psoriasis^[@B25],[@B26]^). Unexpectedly, the patterns of gene expression seen are most consistent with those seen in interferon signaling ([Table 4](#T4){ref-type="table"}).^[@B27],[@B28]^ This approach could be used to determine if there are any temporal variations in the expression profiles or are correlated with comorbidities among patients with chronic urticaria.

CONCLUSIONS
===========

This preliminary study described a method to study gene activation in urticarial lesions and demonstrated a strong inflammatory response with a large variety of activated genes and distinct from that reported with other dermatologic conditions.
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